MEDESIS PHARMA (EPA:ALMDP) | WebDisclosure

Basculer en Français

8404	Companies
122656	Keywords
61079	Articles
65856	Press releases

Home
Companies
MEDESIS PHARMA

REGULATED PRESS RELEASE

published on 11/20/2024 at 17:45, 1 month 10 days ago

MEDESIS PHARMA A FINALISÉ L’ÉTUDE CLINIQUE POUR LE TRAITEMENT DE LA MALADIE D’ALZHEIMER AVEC LE NANOLITHIUM
REGULATED PRESS RELEASE

published on 11/20/2024 at 17:45, 1 month 10 days ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
REGULATED PRESS RELEASE

published on 11/14/2024 at 18:00, 1 month 16 days ago

MEDESIS PHARMA : CONVERSION DE LA PROCÉDURE DE SAUVEGARDE EN REDRESSEMENT JUDICIAIRE
REGULATED PRESS RELEASE

published on 11/12/2024 at 18:00, 1 month 18 days ago

MEDESIS PHARMA : Activités & résultats du 1er semestre 2024
REGULATED PRESS RELEASE

published on 10/08/2024 at 08:00, 2 months 22 days ago

Participation de MEDESIS PHARMA au Congrès mondial pour les études cliniques sur la Maladie d’Alzheimer à Madrid fin octobre 2024 (CTAD - Clinical Trials Alzheimer’s Disease)
REGULATED PRESS RELEASE

published on 10/08/2024 at 08:00, 2 months 22 days ago

MEDESIS PHARMA to participate to the World Congress for Clinical Trials in Alzheimer’s Disease, in Madrid at the end of October 2024 (CTAD, Clinical Trials Alzheimer’s Disease)
BRIEF

published on 09/20/2024 at 08:05, 3 months 10 days ago

Encouraging results from NanoLithium trial on Alzheimer's disease

Biotechnology Alzheimer Nanolithium Clinical Trial Tolérance
BRIEF

published on 09/20/2024 at 08:05, 3 months 10 days ago

Résultats encourageants de l'essai NanoLithium sur la maladie d'Alzheimer

Biotechnologie Alzheimer Nanolithium Essai Clinique Tolérance
REGULATED PRESS RELEASE

published on 09/20/2024 at 08:00, 3 months 10 days ago

MEDESIS PHARMA : Résultats encourageants de la première phase de l’essai clinique de phase 2a pour le traitement de la maladie d’Alzheimer avec le NanoLIthium
Résultats encourageants de l'étude clinique de phase 2a pour le NanoLithium dans le traitement de la maladie d'Alzheimer. Premiers résultats positifs démontrant bonne tolérance et efficacité

Nanolithium Essai Clinique Sécurité Efficacité Maladie D'Alzheimer
REGULATED PRESS RELEASE

published on 09/04/2024 at 17:45, 3 months 26 days ago

MEDESIS PHARMA : MISE À DISPOSITION DES DOCUMENTS PRÉPARATOIRES À L’ASSEMBLÉE GÉNÉRALE MIXTE DU 25 SEPTEMBRE 2024

1 2 ... 4

Accesswire

Published on 12/30/2024 at 18:00, 13 minutes ago

Trust Consulting Services AI Center of Excellence Shifts Focus to Digital Workforce Development in 2025
Published on 12/30/2024 at 17:00, 1 hour 13 minutes ago

Levity Products to Join Arab Health Expo 2025
Published on 12/30/2024 at 15:00, 3 hours 13 minutes ago

Western Alaska Minerals Announces Grant of Options and Restricted Share Units
Published on 12/30/2024 at 14:30, 3 hours 43 minutes ago

Abasca Resources Engages Understood Mineral Resources Ltd. to Complete Flake Graphite Resource Estimate of its Loki Flake Graphite Zone and Grants Stock Options
Published on 12/30/2024 at 13:00, 5 hours 13 minutes ago

SMX is Redefining Ethical Sourcing, KYC, and Data Security in a Tech-Driven World of Fashion and Electronics

View all ACCESSWIRE

EQS Group

Published on 12/30/2024 at 17:45, 28 minutes ago

Eighteenth acquisition in 2024: Mutares has signed an agreement to acquire Nervión Industries, Engineering and Services, S.L.U. from Amper S.A.
Published on 12/30/2024 at 16:50, 1 hour 23 minutes ago

EQS-Adhoc: OTI Greentech AG: Resignation of the chair of the supervisory board
Published on 12/30/2024 at 16:16, 1 hour 56 minutes ago

EQS-Adhoc: OTI Greentech AG: Application for delisting from the open market of the Düsseldorf Stock Exchange resolved
Published on 12/30/2024 at 15:56, 2 hours 16 minutes ago

Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc
Published on 12/30/2024 at 15:55, 2 hours 18 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Spirent Communications plc

Les Echos

Published on 12/30/2024 at 18:00, 13 minutes ago

Groupe CRIT : Finalisation de la transmission générationnelle du contrôle. Information relative au nombre total des droits de vote et d’actions composant le capital social.
Published on 12/30/2024 at 17:45, 28 minutes ago

Disclosure of trading in own shares from December 23th, 2024, to December 27th, 2024. Detailed information per transaction
Published on 12/30/2024 at 17:45, 28 minutes ago

Déclaration des transactions sur actions propres réalisées du 23 décembre 2024 au 27 décembre 2024. Présentation détaillée transaction par transaction
Published on 12/30/2024 at 17:45, 28 minutes ago

Disclosure of trading in own shares from December 23th, 2024, to December 27th, 2024
Published on 12/30/2024 at 17:45, 28 minutes ago

Déclaration des transactions sur actions propres réalisées du 23 décembre 2024 au 27 décembre 2024

View all LES ECHOS COMFI WIRE